Steven Arnold, MD
Psychiatry · Philadelphia, PANPI 1437186327
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $26,444 of the $27,031 with a category attached, or 97.8%. Sage Therapeutics, LLC accounts for 64.4% of it on its own, with 5 other manufacturers making up the rest. 2024 is the largest year on record at $8,990, more than ten times the $36 reported in 2019. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 21 payments — averaging $1287.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sage Therapeutics, LLC$17K
- Merck$6K
- Sanofi US Services Inc.$3K
- Eisai Inc.$622
- Sanofi-aventis U.S. LLC$125
- Eli Lilly$60
Across 222 payments — averaging $18,546 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2.7M
- Novartis$621K
- Ionis Pharmaceuticals, Inc.$523K
- Eli Lilly$174K
- Merck$84K
- Digital Cognition Technologies, Inc.$940
What the payments were for
- Consulting fees$26,44498%
- Travel & lodging$2221%
- Food & beverage$3661%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sage Therapeutics, LLC | 9 | $17,420 |
| Merck | 5 | $6,161 |
| Sanofi US Services Inc. | 1 | $2,644 |
| Eisai Inc. | 4 | $622 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Eli Lilly | 1 | $60 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,031 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 14 | $13,638 |
| Donepezil Hcl | 98 | $961 |
| Memantine Hcl | 23 | $897 |
| Escitalopram Oxalate | 33 | $423 |
| Duloxetine Hcl | 20 | $321 |
| Celecoxib | 12 | $210 |
| Trazodone Hcl | 20 | $64 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Philadelphia
- Daniel WeintraubPhiladelphia$647K
- Michael ThasePhiladelphia$396K
- Freddy AliPhiladelphia$107K
- Richard JaffePhiladelphia$101K
- Ramesh EluriPhiladelphia$85K
- John LaurielloPhiladelphia$62K
- Sidra GhafoorPhiladelphia$56K
- Maria OquendoPhiladelphia$50K
- David OslinPhiladelphia$30K
- Bianca PrevidiPhiladelphia$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.